NASDAQ:ARCTArcturus Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $57.17 +6.71 (+13.30 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$51.53Now: $57.17▼$57.9350-Day Range$29.70MA: $41.70▼$58.2752-Week Range$8.49Now: $57.17▼$62.97Volume1.26 million shsAverage Volume507,293 shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/ABeta3.16 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. The company was founded in 2013 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 1.4 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.14, Arcturus Therapeutics has a potential downside of 35.0% from its current price of $57.17.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesArcturus Therapeutics has received 365 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArcturus Therapeutics has received 328 “underperform” votes. (Add your “underperform” vote.)Community SentimentArcturus Therapeutics has received 52.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $195,388.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 19.20% of the stock of Arcturus Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.81% of the stock of Arcturus Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.71) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -27.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -27.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 45.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARCT Previous Symbol CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone858-900-2660Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.79 million Price / Sales54.70 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book45.02Profitability EPS (Most Recent Fiscal Year)($2.15) Net Income$-25,990,000.00 Net Margins-151.34% Return on Equity-409.05% Return on Assets-58.51%Miscellaneous Employees72 Outstanding Shares19,892,000Market Cap$1.14 billion Next Earnings Date8/20/2020 (Estimated) OptionableOptionable NASDAQ:ARCT Rates by TradingView Receive ARCT News and Ratings via Email Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions How has Arcturus Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARCT shares have increased by 336.7% and is now trading at $57.17. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arcturus Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcturus Therapeutics. When is Arcturus Therapeutics' next earnings date? Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Arcturus Therapeutics. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.08. The biotechnology company had revenue of $2.65 million for the quarter, compared to the consensus estimate of $7.52 million. Arcturus Therapeutics had a negative return on equity of 409.05% and a negative net margin of 151.34%. View Arcturus Therapeutics' earnings history. What price target have analysts set for ARCT? 7 brokerages have issued 12-month target prices for Arcturus Therapeutics' stock. Their forecasts range from $19.00 to $70.00. On average, they expect Arcturus Therapeutics' share price to reach $37.14 in the next twelve months. This suggests that the stock has a possible downside of 35.0%. View analysts' price targets for Arcturus Therapeutics. Has Arcturus Therapeutics been receiving favorable news coverage? Headlines about ARCT stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcturus Therapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Arcturus Therapeutics. Who are some of Arcturus Therapeutics' key competitors? Some companies that are related to Arcturus Therapeutics include Amicus Therapeutics (FOLD), BridgeBio Pharma (BBIO), HYPERA S A/S (HYPMY), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), PTC Therapeutics (PTCT), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Allakos (ALLK), Arena Pharmaceuticals (ARNA), Alkermes (ALKS), Deciphera Pharmaceuticals (DCPH), Axsome Therapeutics (AXSM), Insmed (INSM) and Opko Health (OPK). View all competitors. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Opko Health (OPK), Crispr Therapeutics (CRSP), Pfizer (PFE), Sanofi (SNY), Abbott Laboratories (ABT), Intel (INTC) and Ocular Therapeutix (OCUL). Who are Arcturus Therapeutics' key executives? Arcturus Therapeutics' management team includes the following people: Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)Mr. Andrew H. Sassine, CFO & Director (Age 55)Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance ManagementKeith C. Kummerfeld CPA, VP of Fin. & Corp. Controller What is Arcturus Therapeutics' stock symbol? Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT." Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Dfpg Investments LLC (1.03%) and Harel Insurance Investments & Financial Services Ltd. (0.00%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet and Peter C Farrell. View institutional ownership trends for Arcturus Therapeutics. Which major investors are selling Arcturus Therapeutics stock? ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC. View insider buying and selling activity for Arcturus Therapeutics. Which major investors are buying Arcturus Therapeutics stock? ARCT stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. View insider buying and selling activity for Arcturus Therapeutics. How do I buy shares of Arcturus Therapeutics? Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arcturus Therapeutics' stock price today? One share of ARCT stock can currently be purchased for approximately $57.17. How big of a company is Arcturus Therapeutics? Arcturus Therapeutics has a market capitalization of $1.14 billion and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe. What is Arcturus Therapeutics' official website? The official website for Arcturus Therapeutics is www.arcturusrx.com. How can I contact Arcturus Therapeutics? Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
